EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR EXPOSURE IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: EFFICACY, SAFETY AND RENAL FUNCTION OUTCOME FROM THE TRANSFORM STUDY

被引：0

作者：

Sommerer, C. ^{[1
]}

Arns, W. ^{[1
]}

Weithofer, P. ^{[1
]}

Lehner, F. ^{[1
]}

Banas, B. ^{[1
]}

van der Giet, M. ^{[1
]}

Habicht, A. ^{[1
]}

Renders, L. ^{[1
]}

Rath, T. ^{[1
]}

Bartels, M. ^{[1
]}

Pratschke, J. ^{[1
]}

Hessel, K. ^{[2
]}

Bernhardt, P. ^{[3
]}

Witzke, O. ^{[1
]}

机构：

[1] TRANSFORM Study Grp, Heidelberg, Germany

[2] Novartis Pharma GmbH, Nurnberg, Germany

[3] Novartis Pharma GmbH, Basel, Switzerland

来源：

TRANSPLANT INTERNATIONAL | 2018年 / 31卷

关键词：

D O I：

暂无

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

PV04

引用

页码：18 / 19

页数：2

共 50 条

[21] TRANSFORM: A NOVEL STUDY TO EVALUATE THE EFFECT OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITORS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: BASELINE DATA
Pascual, Julio
TRANSPLANT INTERNATIONAL, 2015, 28 : 442 - 442
[22] Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study (vol 103, pg 1953, 2019)
Tedesco-Silva
TRANSPLANTATION, 2020, 104 (05) : E142 - E142
[23] 2-Year Results on Renal Function and Safety for Everolimus plus Reduced-Exposure Calcineurin Inhibitor in Living Donor Kidney Transplant Recipients
Yagisawa, T.
Ishikawa, N.
Goto, N.
Nakajima, I.
Kamisawa, O.
Fuchinoue, S.
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
[24] Safety and Efficacy of the Early Introduction of Everolimus With Reduced-Exposure Cyclosporine A in De Novo Kidney Recipients
Oh, Chang-Kwon
Huh, Kyu Ha
Ha, Jongwon
Kim, Yeong Hoon
Kim, Yong-Lim
Kim, Yu Seun
TRANSPLANTATION, 2015, 99 (01) : 180 - 186
[25] THE TRANSFORM STUDY: LOWER VIRAL INFECTIONS WITH EVEROLIMUS AND REDUCED CALCINEURIN INHIBITOR VERSUS MYCOPHENOLATE AND STANDARD CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT PATIENTS AT MONTH 12
Buchler, M.
Sommerer, C.
Mulgaonkar, S.
Garcia, V.
Massari, P.
Kuypers, D.
Citterio, F.
Vincenti, F.
Luo, W. L.
Bernhardt, P.
Cruzado, J.
TRANSPLANT INTERNATIONAL, 2018, 31 : 14 - 14
[26] THE TRANSFORM STUDY: LOWER VIRAL INFECTIONS WITH EVEROLIMUS AND REDUCED CALCINEURIN INHIBITOR VERSUS MYCOPHENOLATE AND STANDARD CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT PATIENTS AT MONTH 12
Cruzado, Josep
Mulgaonkar, Shamkant
Garcia, Valter
Massari, Pablo
Kuypers, Dirk
Buchler, Mathias
Citterio, Franco
Vincenti, Flavio
Luo, Wen-Lin
Bernhardt, Peter
Sommerer, Claudia
TRANSPLANT INTERNATIONAL, 2017, 30 : 159 - 160
[27] Efficacy and Safety Outcomes with De Novo Use of Everolimus-Based Regimen in Renal Transplant Recipients with Delayed Graft Function from the TRANSFORM Study.
Chadban, S.
Oppenheimer, F.
Citterio, F.
Witzke, O.
Garcia, V. D.
Gutierrez-Dalmau, A.
Narvekar, P.
Gutierrez, M. P. Hernandez
Bernhardt, P.
Wiseman, A.
AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 357 - 358
[28] Sotrastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients
Tedesco-Silva, H.
Kho, M. M. L.
Hartmann, A.
Vitko, S.
Russ, G.
Rostaing, L.
Budde, K.
Campistol, J. M.
Eris, J.
Krishnan, I.
Gopalakrishnan, U.
Klupp, J.
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (07) : 1757 - 1768
[29] ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus
van der Giet, Markus
Cruzado, Josep M.
de Fijter, Johan W.
Holdaas, Hallvard
Wang, Zailong
Speziale, Antonio
Junge, Guido
OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2014, 6 : 17 - 27
[30] EFFECT OF INDUCTION THERAPY ON OUTCOMES OF DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-DOSE CALCINEURIN INHIBITOR: 24-MONTH RESULTS FROM TRANSFORM STUDY
Pernin, V.
Legendre, C.
Buchler, M.
Oberbauer, R.
Vincenti, F.
Viklicky, O.
Huynh-Do, U.
Kim, D.
Narvekar, P.
Hernandez-Gutierrez, M. P.
Bernhardt, P.
Gharbi, H.
Kuypers, D.
TRANSPLANT INTERNATIONAL, 2020, 33 : 12 - 12

← 1 2 3 4 5 →